Literature DB >> 21040151

Treatment and prognosis of limited disease primary small cell carcinoma of esophagus.

S-B Chen1, J-S Yang, W-P Yang, H-R Weng, H Li, D-T Liu, Y-P Chen.   

Abstract

Primary small cell carcinoma of esophagus (SCCE) is a relatively rare and highly aggressive tumor characterized by early dissemination and poor prognosis. The optimal treatment has not yet been established, and the role of surgery has remained controversial. Most of the limited diseases were treated conventionally by surgery, but the five-year survival rate was still very low. This retrospective study was designed to investigate the clinical characteristics, treatment, and prognostic factors of limited disease SCCE. Clinical data of 40 SCCE patients with clinically limited disease who received transthoracic esophagectomy with lymphadenectomy at the Cancer Hospital of Shantou University Medical College from November 1990 to December 2009 were reviewed to summarize the clinical characteristics and treatment impacted on the survival. Twenty-five cases of the 40 patients were treated with surgery alone, eight cases were treated with surgery + postoperative chemotherapy, four cases were treated with surgery + postoperative radiotherapy, and the other three were treated with surgery + postoperative radiochemotherapy. The Kaplan-Meier and log-rank methods were used to estimate and compare survival rates. Cox's hazard regression model was used to identify the prognostic factors with the entry factors of gender, age (≤ 60 years versus > 60 years), length of the primary lesion (≤ 5 cm versus > 5 cm), location of the primary lesion, macroscopic tumor type, pT, pN, pTNM stage, operation (radical/palliative), and chemotherapy (yes/no). The mean follow-up duration of this series was 24.7 months (1-121 months). Thirty-four patients died of the disease during the follow-up, five were still alive, and one was lost of follow-up. The median survival time of the 40 patients was 13.0 months (95% confidence interval 4.7-21.3), and the 6-, 12-, 24-, 36-, and 60-month overall survival rates (OS) were 77.5%, 56.4%, 28.9%, 23.7%, 10.5%, respectively. In univariate analysis, age (≤ 60 years versus >60 years) (P=0.049), operation (radical/palliative) (P=0.008), and chemotherapy (yes/no) (P= 0.013) significantly influenced the OS of the SCCE patients. In multivariate analysis, operation (P=0.015) and chemotherapy (P=0.031) were independent prognostic factors. The patients who received radical surgery and postoperative chemotherapy had relatively better survival. Surgical resection combined with chemotherapy should be recommended to patients with limited disease SCCE.
© 2010 Copyright the Authors. Journal compilation © 2010, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.

Entities:  

Mesh:

Year:  2010        PMID: 21040151     DOI: 10.1111/j.1442-2050.2010.01112.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  21 in total

1.  Effectiveness of neoadjuvant chemotherapy with etoposide and cisplatin followed by surgery for esophageal neuroendocrine carcinoma: a case report.

Authors:  Miho Yamamoto; Soji Ozawa; Kazuo Koyanagi; Junya Oguma; Akihito Kazuno; Yamato Ninomiya; Kentaro Yatabe; Hiroshi Kajiwara
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

2.  Primary Esophagogastric Neuroendocrine Carcinoma: a Retrospective Study from the Nottingham Upper Gastrointestinal Cancer Center.

Authors:  Constantinos Savva; Philip Kaye; Irshad Soomro; Simon L Parsons; Eleanor James; Srinivasan Madhusudan
Journal:  J Gastrointest Cancer       Date:  2018-03

3.  A rare collision tumor of squamous carcinoma and small cell carcinoma in esophagus involved with separate lymph nodes: a case report.

Authors:  Jingpei Li; Xiaoke Chen; Yaxing Shen; Yingyong Hou; Shumin Zhang; Hao Wang; Mingxiang Feng; Lijie Tan; Qun Wang; Zhaochong Zeng
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 4.  Neuroendocrine Tumors of the Esophagus: State of the Art in Diagnostic and Therapeutic Management.

Authors:  Dimitrios Schizas; Aikaterini Mastoraki; George I Kirkilesis; Athanasios D Sioulas; Ioannis S Papanikolaou; Evangelos P Misiakos; Nikolaos Arkadopoulos; Theodore Liakakos
Journal:  J Gastrointest Cancer       Date:  2017-12

5.  Large-Cell Esophageal Neuroendocrine Carcinoma: Report of a Rare Case.

Authors:  Ilias Galanis; Magdalini Simou; Georgios Floros
Journal:  Cureus       Date:  2022-02-08

6.  Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection.

Authors:  Han-Yu Deng; Peng-Zhi Ni; Yun-Cang Wang; Wen-Ping Wang; Long-Qi Chen
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

7.  The Role of Surgery in Treating Resectable Limited Disease of Esophageal Neuroendocrine Carcinoma.

Authors:  Han-Yu Deng; Gang Li; Jun Luo; Xin-Rui Li; Guha Alai; Yi-Dan Lin
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

8.  Prognostic value of immunohistochemical factors in esophageal small cell carcinoma (ESCC): analysis of clinicopathologic features of 73 patients.

Authors:  Yigong Zhang; Cong Li; Ming Chen
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

9.  Multi-omics profiling of primary small cell carcinoma of the esophagus reveals RB1 disruption and additional molecular subtypes.

Authors:  Susheng Shi; Yibo Gao; Jie He; Renda Li; Zhenlin Yang; Fei Shao; Hong Cheng; Yaru Wen; Sijin Sun; Wei Guo; Zitong Li; Fan Zhang; Liyan Xue; Nan Bi; Jie Wang; Yingli Sun; Yin Li; Fengwei Tan; Qi Xue; Shugeng Gao
Journal:  Nat Commun       Date:  2021-06-18       Impact factor: 14.919

10.  A Retrospective Study of 52 Patients With Primary Small Cell Carcinoma of the Esophagus Treated With Radical Surgery.

Authors:  Ningbo Fan; Zhen Wang; Yuanheng Huang; Zihui Tan; Han Yang; Peng Lin
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.